Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy

Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation–Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation Substudy

Authors of this article:

Phyu Sin Aye¹ ;   Joanne Barnes² ;   George Laking³ ;   Laird Cameron⁴ ;   Malcolm Anderson⁵ ;   Brendan Luey⁶ ;   Stephen Delany⁷ ;   Dean Harris⁸ ;   Blair McLaren⁹ ;   Elliott Brenman¹⁰ ;   Jayden Wong¹¹ ;   Ross Lawrenson¹² ;   Michael Arendse¹³ ;   Sandar Tin Tin¹⁴ ;   Mark Elwood¹⁴ ;   Philip Hope¹⁵ ;   Mark James McKeage^{1, 4, 16}